DK3630761T3 - Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse - Google Patents
Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse Download PDFInfo
- Publication number
- DK3630761T3 DK3630761T3 DK18731624.5T DK18731624T DK3630761T3 DK 3630761 T3 DK3630761 T3 DK 3630761T3 DK 18731624 T DK18731624 T DK 18731624T DK 3630761 T3 DK3630761 T3 DK 3630761T3
- Authority
- DK
- Denmark
- Prior art keywords
- kras
- inhibitors
- methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102200006538 rs121913530 Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762509629P | 2017-05-22 | 2017-05-22 | |
PCT/US2018/033714 WO2018217651A1 (en) | 2017-05-22 | 2018-05-21 | Kras g12c inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3630761T3 true DK3630761T3 (da) | 2022-02-07 |
Family
ID=62620997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18731624.5T DK3630761T3 (da) | 2017-05-22 | 2018-05-21 | Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse |
Country Status (36)
Country | Link |
---|---|
US (3) | US10519146B2 (da) |
EP (2) | EP3974429A1 (da) |
JP (3) | JP6785819B2 (da) |
KR (3) | KR20230128589A (da) |
CN (2) | CN110997668B (da) |
AR (9) | AR111882A1 (da) |
AU (3) | AU2018273356B2 (da) |
BR (1) | BR112019024525B1 (da) |
CA (1) | CA3063469C (da) |
CL (2) | CL2019003394A1 (da) |
CO (1) | CO2019013010A2 (da) |
CR (1) | CR20190534A (da) |
DK (1) | DK3630761T3 (da) |
EA (1) | EA201992781A1 (da) |
ES (1) | ES2905676T3 (da) |
HR (1) | HRP20212017T1 (da) |
HU (1) | HUE057632T2 (da) |
IL (2) | IL270490B (da) |
JO (1) | JOP20190272A1 (da) |
LT (1) | LT3630761T (da) |
MA (1) | MA48772B1 (da) |
MX (2) | MX2019013858A (da) |
NZ (1) | NZ758786A (da) |
PE (1) | PE20200733A1 (da) |
PH (1) | PH12019502579A1 (da) |
PL (1) | PL3630761T3 (da) |
PT (1) | PT3630761T (da) |
RS (1) | RS62800B1 (da) |
SA (2) | SA519410622B1 (da) |
SG (1) | SG10201913195RA (da) |
SI (1) | SI3630761T1 (da) |
TW (1) | TWI780154B (da) |
UA (1) | UA127968C2 (da) |
UY (1) | UY37744A (da) |
WO (1) | WO2018217651A1 (da) |
ZA (3) | ZA201907651B (da) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230150408A (ko) * | 2016-12-22 | 2023-10-30 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
TWI731264B (zh) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
CA3095494C (en) | 2018-04-04 | 2023-11-07 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7266043B2 (ja) * | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
MA52564A (fr) * | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
MX2020012204A (es) * | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
CA3104654A1 (en) | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
KR20210024587A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 나프티리디논 화합물 |
JP2020090482A (ja) * | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MX2021006841A (es) | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. |
WO2020156285A1 (zh) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药(苏州)股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
EP4249000A3 (en) | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
WO2020219606A1 (en) * | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
CN113767106B (zh) * | 2019-04-28 | 2024-02-20 | 劲方医药科技(上海)有限公司 | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 |
EP3738593A1 (en) * | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
AU2020277398A1 (en) | 2019-05-21 | 2021-12-09 | Amgen Inc. | Solid state forms |
BR112021023136A2 (pt) * | 2019-05-21 | 2022-01-04 | Inventisbio Co Ltd | Compostos heterocíclicos, métodos de preparação e usos dos mesmos |
CN113423703A (zh) * | 2019-05-29 | 2021-09-21 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
CN112552294B (zh) * | 2019-09-10 | 2023-12-19 | 上海翰森生物医药科技有限公司 | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 |
CN113396147A (zh) * | 2019-05-31 | 2021-09-14 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
JP2022539341A (ja) * | 2019-06-24 | 2022-09-08 | クヮントン ニューオップ バイオファーマシューティカルズ カンパニー, リミテッド | Kras g12cの阻害剤としての複素環式化合物 |
US20220372036A1 (en) * | 2019-06-25 | 2022-11-24 | Medshine Discovery Inc. | Seven-membered heterocyclic derivative acting as kras g12c mutant protein inhibitor |
CN110256421A (zh) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
WO2021000885A1 (zh) * | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
US20220298174A1 (en) * | 2019-08-02 | 2022-09-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Tetracyclic compound, preparation method therefor and use thereof |
TWI752580B (zh) * | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
CN112390797A (zh) * | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
CN112390796B (zh) * | 2019-08-19 | 2023-06-27 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
EP4029853A4 (en) | 2019-09-11 | 2023-03-01 | Chiral Quest (suzhou) Co., Ltd. | SYNTHETIC METHOD APPLIED TO A HETEROCYCLIC INTERMEDIATE OF KRAS INHIBITOR DRUGS |
CN114728968A (zh) * | 2019-09-20 | 2022-07-08 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
JP2022548791A (ja) | 2019-09-24 | 2022-11-21 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
CN112225734B (zh) * | 2019-10-25 | 2021-12-07 | 南京瑞捷医药科技有限公司 | Kras g12c抑制剂及其用途 |
MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
CA3156777A1 (en) * | 2019-10-30 | 2021-05-06 | Fusheng ZHOU | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
TWI760919B (zh) * | 2019-11-15 | 2022-04-11 | 大陸商四川海思科製藥有限公司 | 一種嘧啶並環衍生物及其在醫藥上的應用 |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
KR20220133866A (ko) | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
CN111377918B (zh) * | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2021104431A1 (zh) * | 2019-11-29 | 2021-06-03 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
WO2021113595A1 (en) * | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
CN115666563A (zh) * | 2019-12-10 | 2023-01-31 | 得克萨斯系统大学评议会 | 作为kras抑制剂的取代的7-(哌嗪-1-基)吡唑并[1,5-a]嘧啶类似物的组合物和方法 |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
WO2021120045A1 (en) * | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
WO2021121367A1 (en) * | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
WO2021139678A1 (zh) * | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
CN113087700B (zh) * | 2020-01-08 | 2023-03-14 | 苏州亚盛药业有限公司 | 螺环四氢喹唑啉 |
CN111205286B (zh) * | 2020-01-13 | 2022-12-13 | 中科苏州药物研究院 | 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用 |
CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
CN115003668A (zh) * | 2020-01-21 | 2022-09-02 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
CN112159405B (zh) | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
CN113248521B (zh) * | 2020-02-11 | 2023-07-18 | 上海和誉生物医药科技有限公司 | 一种k-ras g12c抑制剂及其制备方法和应用 |
US20230143751A1 (en) | 2020-02-24 | 2023-05-11 | Shanghai Zheye Biotechnology Co. Ltd. | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs |
CN114901663A (zh) * | 2020-03-02 | 2022-08-12 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
TW202144345A (zh) * | 2020-03-17 | 2021-12-01 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
JP7461499B2 (ja) * | 2020-04-03 | 2024-04-03 | メッドシャイン ディスカバリー インコーポレイテッド | オクタヒドロピラジノジアザナフチリジンジオン化合物 |
CN115427414A (zh) * | 2020-04-28 | 2022-12-02 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
JP2023526443A (ja) | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ron変異が関与する非小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 |
CN112574199B (zh) * | 2020-05-20 | 2021-05-18 | 首药控股(北京)股份有限公司 | Kras-G12C抑制剂杂环化合物 |
WO2021236920A1 (en) | 2020-05-20 | 2021-11-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of amg-510 and process for preparation thereof |
US11945812B2 (en) | 2020-06-02 | 2024-04-02 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
CN114585624A (zh) * | 2020-06-02 | 2022-06-03 | 上海喆邺生物科技有限公司 | 一种手性中间体及其制备方法 |
WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
US20230233568A1 (en) | 2020-06-24 | 2023-07-27 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
CN115996717A (zh) * | 2020-06-25 | 2023-04-21 | 托雷莫治疗股份公司 | 用于治疗癌症的cbp/p300溴结构域抑制剂和kras抑制剂的组合 |
CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
EP4194452A1 (en) | 2020-08-02 | 2023-06-14 | Shanghai Zheye Biotechnology Co., Ltd. | Aromatic compound and application thereof in antitumor drug |
US20230295163A1 (en) * | 2020-08-21 | 2023-09-21 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Tetracyclic derivative, method for preparing same and use thereof in medicine |
CN114075195A (zh) * | 2020-08-21 | 2022-02-22 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
WO2022047093A1 (en) * | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
WO2022076623A1 (en) | 2020-10-07 | 2022-04-14 | Amgen Inc. | Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
WO2022093856A1 (en) | 2020-10-27 | 2022-05-05 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
CA3201521A1 (en) * | 2020-11-13 | 2022-05-19 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors |
AU2021382674A1 (en) | 2020-11-20 | 2023-06-22 | Amgen Inc. | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof[2,3-d]pyrimidine-2,4(1h,3h)-dione |
TW202227412A (zh) * | 2020-11-24 | 2022-07-16 | 大陸商杭州多域生物技術有限公司 | 一種芳香化合物、其製備方法及應用 |
TW202227438A (zh) * | 2020-11-24 | 2022-07-16 | 大陸商杭州多域生物技術有限公司 | 一種芳香化合物、其製備方法及應用 |
TW202229278A (zh) * | 2020-11-26 | 2022-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜環類衍生物的鹽、晶型及其製備方法和應用 |
WO2022121839A1 (zh) * | 2020-12-08 | 2022-06-16 | 上海和誉生物医药科技有限公司 | 吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用 |
WO2022125971A1 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
WO2022127847A1 (zh) * | 2020-12-17 | 2022-06-23 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
WO2022127915A1 (zh) * | 2020-12-18 | 2022-06-23 | 正大天晴药业集团股份有限公司 | 吡啶并嘧啶酮类化合物 |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN114685502A (zh) * | 2020-12-25 | 2022-07-01 | 由理生物医药(上海)有限公司 | 作为kras-g12c抑制剂的螺环类化合物 |
WO2022150628A1 (en) | 2021-01-08 | 2022-07-14 | Amgen Inc. | Use of a kras g12c inhibitor in treating cancers |
AU2022234388A1 (en) * | 2021-03-10 | 2023-10-26 | Beta Pharma, Inc. | Pyridopyrimidine derivatives as kras inhibitors |
WO2022188849A1 (en) * | 2021-03-11 | 2022-09-15 | InventisBio Co., Ltd. | Solid dispersions |
CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
CN117479942A (zh) | 2021-04-09 | 2024-01-30 | 勃林格殷格翰国际有限公司 | 抗癌疗法 |
EP4329749A1 (en) * | 2021-04-27 | 2024-03-06 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
EP4329888A1 (en) | 2021-04-29 | 2024-03-06 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
EP4341260A1 (en) | 2021-05-19 | 2024-03-27 | Teva Pharmaceuticals International GmbH | Process for preparation of sotorasib and solid state form thereof |
TW202313048A (zh) * | 2021-05-19 | 2023-04-01 | 美商建南德克公司 | 組合療法 |
AU2022280025A1 (en) * | 2021-05-25 | 2023-12-07 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
AR126166A1 (es) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
EP4227305A1 (en) | 2022-02-10 | 2023-08-16 | Sandoz AG | Crystalline form of sotorasib |
EP4359410A1 (en) | 2021-06-24 | 2024-05-01 | Sandoz Ag | Crystalline form of sotorasib |
WO2023018810A1 (en) * | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
CN114605406B (zh) * | 2021-09-18 | 2023-05-26 | 都创(上海)医药开发有限公司 | Amg510化合物的晶型及其制备方法和用途 |
US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg反向激動劑及其用途 |
WO2023078424A1 (zh) * | 2021-11-05 | 2023-05-11 | 苏州信诺维医药科技股份有限公司 | Kras突变体抑制剂的晶型、其制备方法及其应用 |
TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
TW202340212A (zh) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023122662A1 (en) | 2021-12-22 | 2023-06-29 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
WO2023117681A1 (en) | 2021-12-22 | 2023-06-29 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds for the treatment of cancer |
US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023159086A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023159087A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023172858A1 (en) | 2022-03-07 | 2023-09-14 | Amgen Inc. | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2023194310A1 (en) | 2022-04-04 | 2023-10-12 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
US11795173B1 (en) | 2022-04-28 | 2023-10-24 | Xinthera, Inc. | Substituted pyridines as PARP1 inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
CN115368358A (zh) * | 2022-09-01 | 2022-11-22 | 浙江九洲药业股份有限公司 | 一种Sotorasib新晶型及其制备方法与应用 |
WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232027A (en) | 1979-01-29 | 1980-11-04 | E. R. Squibb & Sons, Inc. | 1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives |
DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
GB8912336D0 (en) | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
CA2066898A1 (en) | 1991-04-29 | 1992-10-30 | Chuan Shih | Pharmaceutical compounds |
EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
JP3560609B2 (ja) | 1992-11-13 | 2004-09-02 | イミュネックス・コーポレーション | Elkリガンドと呼ばれる新規なサイトカイン |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
DE69423781T2 (de) | 1993-12-17 | 2000-08-10 | Novartis Ag | Rapamycin-derivate als immunosuppressoren |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
EP1464706A3 (en) | 1994-04-15 | 2004-11-03 | Amgen Inc., | HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases |
DK0682027T3 (da) | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
DK0819129T3 (da) | 1995-04-03 | 2000-10-23 | Novartis Ag | Pyrazolderivater og fremgangsmåde til deres fremstilling |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag | Rapamycinderivate |
CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
EP0888349B1 (en) | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
BR9709443B1 (pt) | 1996-03-15 | 2009-05-05 | n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas. | |
CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
DK0938486T3 (da) | 1996-08-23 | 2008-07-07 | Novartis Ag | Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
WO1998014450A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
US6329375B1 (en) | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
US6509173B1 (en) | 1997-10-21 | 2003-01-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
WO1999045009A1 (en) | 1998-03-04 | 1999-09-10 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
WO1999061422A1 (en) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
EP1097147A4 (en) | 1998-07-10 | 2001-11-21 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
CA2341409A1 (en) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
CA2366857C (en) | 1999-03-30 | 2010-12-14 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
NZ516258A (en) | 1999-06-07 | 2004-02-27 | Immunex Corp | Tek antagonists |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
DE60036945T2 (de) | 1999-07-12 | 2008-08-21 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
CN1293081C (zh) | 1999-08-24 | 2007-01-03 | 阿里亚德基因治疗公司 | 28-表雷帕霉素类似物,其制备方法,药物组合物和用途 |
DK1676845T3 (da) | 1999-11-05 | 2008-09-15 | Astrazeneca Ab | Nye quinazolinderivater |
DK1233943T3 (da) | 1999-11-24 | 2011-08-15 | Sugen Inc | Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander |
US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
AU2001247219B2 (en) | 2000-02-25 | 2007-01-04 | Immunex Corporation | Integrin antagonists |
BRPI0112584B8 (pt) | 2000-07-19 | 2021-05-25 | Warner Lambert Co | ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
CZ304059B6 (cs) | 2000-12-21 | 2013-09-11 | Glaxo Group Limited | Deriváty pyrimidinu a farmaceutický prostredek |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
JP2002233610A (ja) | 2002-02-18 | 2002-08-20 | Olympia:Kk | スロットマシン |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US20050009849A1 (en) | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Gitr 리간드, gitr 리간드-연관 분자, 항체 및그의 용도 |
ES2316995T3 (es) | 2003-07-08 | 2009-04-16 | Novartis Ag | Uso de rapamicina y derivados de rapamicida para el tratamiento de la perdida osea. |
WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
WO2005016252A2 (en) | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
MXJL06000006A (es) | 2003-08-22 | 2006-05-04 | Avanir Pharmaceuticals | Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre. |
JP2007518399A (ja) | 2003-12-02 | 2007-07-12 | ジェンザイム コーポレイション | 肺癌を診断および治療する組成物並びに方法 |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
CN101023064B (zh) | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
GT200500287A (es) | 2004-10-13 | 2006-04-17 | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
US7354944B2 (en) | 2004-10-18 | 2008-04-08 | Amgen Inc. | Thiadiazole compounds and methods of use |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
DK2161336T4 (da) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død 1(PD-1) samt fremgangsmåder til behandling af kræft under brug af anti-PD-1 antistoffer alene eller kombineret med andre immunterapier |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
WO2007034327A1 (en) | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
JP5199885B2 (ja) | 2006-01-18 | 2013-05-15 | アムジエン・インコーポレーテツド | プロテインキナーゼb(pkb)阻害剤としてのチアゾール化合物 |
EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
TWI499420B (zh) | 2006-12-07 | 2015-09-11 | Hoffmann La Roche | 肌醇磷脂3-激酶抑制劑化合物及使用方法 |
CA2680783C (en) | 2007-03-23 | 2012-04-24 | Amgen Inc. | Heterocyclic compounds and their uses |
RS54706B1 (en) | 2007-03-23 | 2016-08-31 | Amgen Inc. | HETEROCYCLIC UNITS AND THEIR USES |
PT2139882E (pt) | 2007-03-23 | 2014-01-30 | Amgen Inc | Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k) |
WO2008153947A2 (en) | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
CA2693473A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
AU2008282728B2 (en) | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
RU2523890C2 (ru) | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
PE20091268A1 (es) | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
WO2010030002A1 (ja) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性gitrリガンド発現細胞 |
US20110263647A1 (en) | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
MX2011008674A (es) | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
JP2012531435A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体 |
UY32742A (es) | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのpi3k活性阻害剤としての使用 |
EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
CN102869361A (zh) | 2009-09-11 | 2013-01-09 | 安姆根有限公司 | 用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
WO2011075747A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
CN105693861A (zh) | 2009-12-29 | 2016-06-22 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
EP2696682B1 (en) | 2011-04-13 | 2018-03-21 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
AU2013301865B2 (en) | 2012-08-07 | 2017-08-17 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
MX364438B (es) | 2013-03-15 | 2019-04-26 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
BR112016008016B8 (pt) * | 2013-10-10 | 2023-09-26 | Araxes Pharma Llc | Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
BR112016016421B1 (pt) | 2014-01-20 | 2022-10-18 | Cleave Biosciences, Inc | Composto de pirimidina fundida, composição farmacêutica e respectivos uso |
WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
WO2016161361A1 (en) | 2015-04-03 | 2016-10-06 | Nantbioscience, Inc. | Compositions and methods of targeting mutant k-ras |
EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
EP3325447A1 (en) | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Rasの阻害剤としての複素環式化合物およびその使用方法 |
KR20230150408A (ko) * | 2016-12-22 | 2023-10-30 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
JP2020505395A (ja) | 2017-01-26 | 2020-02-20 | アラクセス ファーマ エルエルシー | 縮合n−複素環式化合物およびその使用方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
TWI731264B (zh) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7266043B2 (ja) * | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
JP2021528404A (ja) | 2018-06-21 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤化合物 |
WO2019243533A1 (en) | 2018-06-21 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
AU2020277398A1 (en) | 2019-05-21 | 2021-12-09 | Amgen Inc. | Solid state forms |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
-
2017
- 2017-06-16 JO JOP/2019/0272A patent/JOP20190272A1/ar unknown
-
2018
- 2018-05-21 PE PE2019002456A patent/PE20200733A1/es unknown
- 2018-05-21 NZ NZ758786A patent/NZ758786A/en unknown
- 2018-05-21 CR CR20190534A patent/CR20190534A/es unknown
- 2018-05-21 UA UAA201912099A patent/UA127968C2/uk unknown
- 2018-05-21 EA EA201992781A patent/EA201992781A1/ru unknown
- 2018-05-21 CN CN201880047910.1A patent/CN110997668B/zh active Active
- 2018-05-21 DK DK18731624.5T patent/DK3630761T3/da active
- 2018-05-21 PL PL18731624T patent/PL3630761T3/pl unknown
- 2018-05-21 EP EP21201361.9A patent/EP3974429A1/en active Pending
- 2018-05-21 HR HRP20212017TT patent/HRP20212017T1/hr unknown
- 2018-05-21 SI SI201830527T patent/SI3630761T1/sl unknown
- 2018-05-21 BR BR112019024525-1A patent/BR112019024525B1/pt active IP Right Grant
- 2018-05-21 KR KR1020237029215A patent/KR20230128589A/ko active Application Filing
- 2018-05-21 US US15/984,855 patent/US10519146B2/en active Active
- 2018-05-21 WO PCT/US2018/033714 patent/WO2018217651A1/en unknown
- 2018-05-21 MX MX2019013858A patent/MX2019013858A/es unknown
- 2018-05-21 RS RS20220019A patent/RS62800B1/sr unknown
- 2018-05-21 AU AU2018273356A patent/AU2018273356B2/en active Active
- 2018-05-21 SG SG10201913195RA patent/SG10201913195RA/en unknown
- 2018-05-21 CA CA3063469A patent/CA3063469C/en active Active
- 2018-05-21 PT PT187316245T patent/PT3630761T/pt unknown
- 2018-05-21 CN CN202211265391.0A patent/CN115626923A/zh active Pending
- 2018-05-21 KR KR1020197037502A patent/KR102300499B1/ko active IP Right Grant
- 2018-05-21 MA MA48772A patent/MA48772B1/fr unknown
- 2018-05-21 TW TW107117297A patent/TWI780154B/zh active
- 2018-05-21 ES ES18731624T patent/ES2905676T3/es active Active
- 2018-05-21 LT LTEPPCT/US2018/033714T patent/LT3630761T/lt unknown
- 2018-05-21 KR KR1020217028358A patent/KR102573230B1/ko active IP Right Grant
- 2018-05-21 EP EP18731624.5A patent/EP3630761B1/en active Active
- 2018-05-21 HU HUE18731624A patent/HUE057632T2/hu unknown
- 2018-05-22 AR ARP180101353A patent/AR111882A1/es active IP Right Grant
- 2018-05-22 UY UY0001037744A patent/UY37744A/es unknown
- 2018-05-22 JP JP2018097648A patent/JP6785819B2/ja active Active
-
2019
- 2019-10-23 US US16/661,907 patent/US20200055845A1/en not_active Abandoned
- 2019-11-07 IL IL270490A patent/IL270490B/en unknown
- 2019-11-18 PH PH12019502579A patent/PH12019502579A1/en unknown
- 2019-11-19 ZA ZA2019/07651A patent/ZA201907651B/en unknown
- 2019-11-20 MX MX2021011115A patent/MX2021011115A/es unknown
- 2019-11-20 CO CONC2019/0013010A patent/CO2019013010A2/es unknown
- 2019-11-21 CL CL2019003394A patent/CL2019003394A1/es unknown
- 2019-11-24 SA SA519410622A patent/SA519410622B1/ar unknown
- 2019-11-24 SA SA522432081A patent/SA522432081B1/ar unknown
-
2020
- 2020-09-17 CL CL2020002405A patent/CL2020002405A1/es unknown
- 2020-09-24 US US17/031,607 patent/US11905281B2/en active Active
- 2020-10-27 JP JP2020179494A patent/JP7095052B2/ja active Active
-
2021
- 2021-01-29 ZA ZA2021/00644A patent/ZA202100644B/en unknown
- 2021-06-28 AR ARP210101805A patent/AR122789A2/es unknown
- 2021-06-28 AR ARP210101804A patent/AR122788A2/es unknown
- 2021-06-28 AR ARP210101799A patent/AR122783A2/es unknown
- 2021-06-28 AR ARP210101806A patent/AR122790A2/es unknown
- 2021-06-28 AR ARP210101802A patent/AR122786A2/es unknown
- 2021-06-28 AR ARP210101801A patent/AR122785A2/es unknown
- 2021-06-28 AR ARP210101800A patent/AR122784A2/es unknown
- 2021-06-28 AR ARP210101803A patent/AR122787A2/es unknown
- 2021-10-06 AU AU2021245150A patent/AU2021245150B2/en active Active
-
2022
- 2022-02-07 IL IL290399A patent/IL290399B2/en unknown
- 2022-03-02 ZA ZA2022/02559A patent/ZA202202559B/en unknown
- 2022-06-21 JP JP2022099389A patent/JP2022126763A/ja active Pending
-
2023
- 2023-11-09 AU AU2023263502A patent/AU2023263502A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3630761T3 (da) | Kras-g12c-inhibitorer og fremgangsmåder til anvendelse af disse | |
DK3842442T3 (da) | Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet | |
DK3259386T3 (da) | Systemer og fremgangsmåder til udførelse af immunoassays | |
DK3782639T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
DK3398022T3 (da) | Systemer og fremgangsmåder til tilpasning af uav-bane | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
DK3378273T3 (da) | Fremgangsmåder og indretninger til udførelse af en genoptagelsesprocedure | |
DK3129912T3 (da) | Fremgangsmåde og system til sikring af data | |
DK3426109T3 (da) | Samling og fremgangsmåde til opskumning af fluid | |
DK3329203T3 (da) | Fremgangsmåde og anordning til rensning af rørbundter | |
DK3402483T3 (da) | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler | |
DK3519572T3 (da) | Forbindelser og fremgangsmåder til reduktion af tau-ekspression | |
DK3319948T3 (da) | Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse | |
DK3177608T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
DK3254093T3 (da) | Fremgangsmåde og anordning til bestemmelse af vandindhold | |
DK3606760T3 (da) | Indretning og fremgangsmåde til belægning af overflader | |
DK3393688T3 (da) | Fremgangsmåde og indretning til genindvinding af salt | |
DK3318001T3 (da) | Fremgangsmåder og indretninger til håndtering af hash-tree-baserede datasignaturer | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3311337T3 (da) | Fremgangsmåder og en computerindretning til bestemmelse af ægtheden af et mærke | |
DK3319949T3 (da) | Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse | |
DK3132049T3 (da) | Enhed og fremgangsmåder til anvendelse af enhed til detektering af aminoacidopatier | |
DK3366831T3 (da) | Indretning og fremgangsmåde til identifikation af en stoftype | |
DK3285061T3 (da) | Fremgangsmåde og indretning til hårdhedsafprøvning |